Published December 2018 | Version v1
Journal article

Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors

  • 1. Tokai University, Department of Radiation Oncology, School of Medicine (Japan)
  • 2. National Cancer Center Hospital, Department of Radiation Oncology (Japan)
  • 3. Niigata University Graduate School of Medical and Dental Sciences, Department of Radiology and Radiation Oncology (Japan)
  • 4. University of the Ryukyus, Department of Radiology, Graduate School of Medical Science (Japan)
  • 5. Japanese Red Cross Nagasaki Genbaku Hospital, Department of Radiotherapy (Japan)
  • 6. Niigata Cancer Center Hospital, Department of Radiation Oncology (Japan)
  • 7. University of Yamanashi, Department of Radiology (Japan)
  • 8. Hokkaido University, Department of Radiation Medicine, Graduate School of Medicine (Japan)
  • 9. Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Department of Radiation Oncology (Japan)
  • 10. Teikyo University Mizonokuchi Hospital, Department of Radiology (Japan)
  • 11. Nippon Medical School Hospital, Division of Radiation Therapy (Japan)

Description

Background

To determine the current practice of stereotactic irradiation (STI) for brain metastases in Japan by a questionnaire survey.

Methods

A questionnaire was distributed to 313 institutions performing STI with one of the following machines: Gamma Knife (GK), CyberKnife (CK), Novalis (Nov), or other linear accelerator (LINAC)-based systems (OLS). The participation was voluntary.

Results

There were 163 responding institutions. The total number of STI treatments between April 2013 and March 2014 was 10,684. Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) were performed in 8624 (80.7%) and 2060 (19.3%) cases, respectively. Whole-brain radiation therapy (WBRT) was performed for a total of 3515 cases. For a case model of a 1.5-cm solitary brain metastasis in a non-eloquent area, the most common GTV-PTV margin was 2 mm (22 of 114 institutions), and an institutional standard fraction was 1 (75 of 114 institutions). The doses for the model case also varied from 13.0 to 26.0 Gy (Median 20 Gy) when converted to SRS (α/β = 10). A prescription point was at the PTV margin the most. The median dose constraints which were converted to SRS (α/β = 3) to organs at risk were 12.2, 12.7, and 13.7 Gy for optic nerves, cavernous sinus, and brainstem, respectively.

Conclusions

STI for brain metastases in current practice varied significantly among institutions. These different strategies relied mostly on the type of treatment machine used. It is thus necessary to establish a common guideline to express dose prescriptions and plan qualities for different STI machines.

Additional details

Identifiers

Publishing Information

Journal Title
International Journal of Clinical Oncology
Journal Volume
23
Journal Issue
6
Journal Page Range
p. 1015-1022
ISSN
1341-9625

INIS

Country of Publication
Japan
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
54118573
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BRAIN; IRRADIATION; LIMITING VALUES; LINEAR ACCELERATORS; METASTASES; NEOPLASMS; NERVES; RADIOTHERAPY; RECOMMENDATIONS; SINUSES; SURGERY
Descriptors DEC
ACCELERATORS; BODY; CAVITIES; CENTRAL NERVOUS SYSTEM; DISEASES; MEDICINE; NERVOUS SYSTEM; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2018 Japan Society of Clinical Oncology
Collaborations
The Japanese Radiation Oncology Study Group (JROSG) Working Subgroup for Neurological Tumors